DaVita Inc. (DVA) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is constructive — consensus is a manageable bar after Q1's large beat, and the biggest swing factor is whether the Fresenius patient-transfer tailwind fully materializes in Q2 volume, which management guided would be the peak benefit quarter.

DaVita heads into Q2 2026 earnings with momentum from a strong Q1 beat (adjusted OI ~$50M ahead of forecast, adjusted EPS of $2.87 vs. consensus ~$2.37) and a subsequent guidance raise, yet the bar for Q2 is now higher — consensus sits at ~$3.85 adjusted EPS and ~$580M adjusted OI, both modestly above the implied Q2 run-rate embedded in the raised full-year range of $2.15–$2.25B. Management guided that OI would be "about evenly split" across the three remaining quarters, implying a Q2 target of roughly $550–$580M, so consensus is tracking near the high end of that range. The tone from the May 12 BofA Healthcare Conference was confident: CFO Joel Ackerman reiterated the 3–7% OI growth algorithm, confirmed ~$50M phosphate binder OI contribution for 2026, and noted that the Fresenius clinic closures — expected to be "largely closed by end of Q2" — would deliver most of their patient-transfer benefit in Q2 and Q3, with the annualization point around end of April/May. Estimate revisions have been essentially flat since the post-Q1 reset (EPS consensus moved from $3.87 to $3.85 in the week after earnings and has not moved since), suggesting the street is comfortable with the bar but not aggressively raising numbers. The stock has re-rated sharply (+53% since Q1 earnings), trading at ~14.7x NTM P/E vs. ~10.5x three months ago, meaning the multiple has done most of the work and the stock needs the volume/RPT story to hold. The key wildcard is the

ACA enhanced premium tax credit headwind: management held its $40M full-year headwind assumption despite Q1 commercial mix coming in flat, and Q2 is the quarter where the headwind was expected to begin building — any upside surprise here (or confirmation that the headwind is tracking below $40M) could be the incremental positive catalyst, while a worse-than-expected commercial mix deterioration would pressure RPT and the full-year guide.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a

Key Takeaway: Consensus is a moderately high but achievable bar — the Q1 beat was unusually large and some timing benefit reverses in Q2, but the Fresenius transfer tailwind and continued labor productivity should offset.

Treatment volume growth is the bigger swing factor: Q2 is the peak Fresenius benefit quarter, and any shortfall there flows directly to OI.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data

Table 2 — Beat/Miss History (Last 8 Quarters)

Top KPI 1: Adjusted Operating Income (OI) | Top KPI 2: Adjusted EPS (Diluted, Operating)

Pattern: DVA has beaten on OI in 5 of the last 7 reported quarters, with the two misses (Q3 2024, Q3 2025) driven by timing/seasonality rather than structural deterioration. The Q1 2026 beat was the largest in recent history (+21% EPS surprise), setting a higher bar for Q2. Sources: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was formally raised on May 5 (Q1 earnings) and has not changed since; the May 12 BofA conference confirmed the same numbers with a

Key Takeaway: Guidance was formally raised on May 5 (Q1 earnings) and has not changed since; the May 12 BofA conference confirmed the same numbers with a confident tone. The only open question is whether the ACA headwind tracks below the $40M placeholder, which management flagged as trending slightly better but chose not to formally revise.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been remarkably stable since the post-Q1 reset — Q2 EPS consensus moved from $3.87 to $3.85 in the first week after earnings and has not moved since, suggesting the street is comfortable with the bar but sees limited upside from here. The full-year OI consensus of $2,244M sits near the top of the raised guidance range ($2,150–$2,250M), implying the street is already pricing in a slight beat on the year.

Estimates have been essentially frozen since the post-Q1 reset, with both Q2 and FY consensus drifting only ~50 bps lower in the 12 weeks since earnings — a sign of high conviction in the current bar rather than creeping skepticism. The full-year OI consensus of $2,244M sits near the top of the raised guidance range, implying the street is already embedding a modest beat on the year; any Q2 shortfall would therefore require a meaningful H2 acceleration to hold the full-year number. Sources: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: The DVA re-rating since Q1 earnings has been almost entirely

Key Takeaway: The DVA re-rating since Q1 earnings has been almost entirely

Key Takeaway: The DVA re-rating since Q1 earnings has been almost entirely multiple expansion (+40% P/E expansion over 3 months), not estimate revisions — the stock has outperformed XLV by ~40 percentage points since May 5, meaning the bar for Q2 to sustain the move is high and the stock is now pricing in execution, not just optionality.

DVA closed at $157.04 on May 5, 2026 (Q1 earnings day), and reached $240.09 by July 31, 2026 — a gain of +52.9% in approximately 60 trading days. Over the same period, XLV (Health Care Select Sector SPDR ETF, the appropriate sector benchmark for a large-cap healthcare services company) gained approximately +11.9%, and the S&P 500 (SPY) gained approximately +3.2%. DVA's outperformance vs. XLV of ~41 percentage points is almost entirely attributable to multiple expansion: the NTM P/E expanded from ~8.2x at the time of Q1 earnings to ~14.7x currently, while NTM EPS estimates moved only modestly. The stock briefly pulled back in mid-May (to ~$192) and again in early June (to ~$188) before resuming its uptrend, with the June–July leg driven by continued momentum and the Berkshire/Weschler portfolio narrative. The stock is now trading near its 52-week high and at a meaningful premium to its historical average multiple, making Q2 execution critical to sustaining the valuation.

Sector ETF used: XLV (Health Care Select Sector SPDR ETF) — appropriate for DVA as a large-cap US healthcare services/dialysis provider. Source: Stock Price Data (Yahoo Finance).

DVA vs. XLV vs. S&P 500 — Indexed Performance Since Q1 2026 Earnings (May 5, 2026)

Note: Indexed to 100 at May 5, 2026 close. Data through July 31, 2026 only. DVA +52.9%, XLV +11.9%, SPY +3.2% over the period. Source: Stock Price Data (Yahoo Finance).

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the

Key Takeaway: The most important post-Q1 development is the confirmation that Fresenius clinic closures are proceeding on schedule (largely complete by end of Q2), which is the primary incremental volume driver for Q2 and the key upside catalyst heading into the print. No guidance changes or negative surprises have emerged since May 5.

• August 3, 2026 — Fresenius Medical Care (FMS) Reports Q2 2026 Results: FMS confirmed its unchanged full-year 2026 financial outlook and reported Q2 operating income (ex-special items) of EUR 569M, up 23% at constant currency, with Care Delivery segment stronger than market expected.
• Implication: Stable FMS outlook confirms no deterioration in the renal care reimbursement environment; strong Care Delivery OI growth is a positive read-through for dialysis industry economics heading into DVA's Q2 print.
• July 21, 2026 — DVA Schedules Q2 2026 Earnings Call: DaVita confirmed August 4, 2026 at 5:00 PM ET for Q2 results and conference call. No pre-announcement or guidance update was included.
• Implication: Absence of a pre-announcement (positive or negative) is consistent with results tracking within the guided range.
• June 30, 2026 — Berkshire/Weschler Portfolio Coverage (Barron’s): Barron’s highlighted that Berkshire manager Ted Weschler is having a strong 2026, with DVA up over 90% YTD as a key holding.
• Implication: Elevated investor attention on DVA as a Berkshire-affiliated name; Berkshire sold ~1.2M shares in May (see Insider section) but remains a ~28.9M share holder, keeping the stock in the spotlight.
• June 17, 2026 — CEO Javier Rodriguez Open-Market Sales: CEO Rodriguez sold ~69,407 shares (~$30K + $39K shares) on June 15–16 at prices in the ~$208–$211 range (see Insider section).
• Implication: Discretionary sales by the CEO at prices well below current levels (~$240) are notable; no 10b5-1 plan flagged, though the timing (6 weeks post-earnings) is not unusual for post-blackout window selling.
• May 12, 2026 — BofA Global Healthcare Conference: CFO Joel Ackerman presented and confirmed all Q1 guidance raises, elaborated on Fresenius transfer timing (annualization from end of April/May), reiterated $50M phosphate binder OI contribution for 2026, and confirmed AI is a net cost through 2026–2027.
• Implication: No incremental guidance change, but the conference provided important color on Q2 phasing — Fresenius benefit expected to be the largest in Q2/Q3, and commercial mix headwind expected to build through the year.
• May 5–6, 2026 — Q1 2026 Earnings Beat & Guidance Raise: DVA reported Q1 adjusted OI of $482M (+$50M vs. forecast), raised FY OI guidance to $2,150–$2,250M (+$40M at midpoint), raised FY EPS guidance to $14.10–$15.20, and raised volume growth guidance from flat to +25–50 bps. Stock surged ~23% the following day.
• Implication: This is the baseline event that reset the bar for Q2; the magnitude of the beat and the guidance raise set a higher hurdle for Q2 to sustain the re-rating.
• May 5, 2026 — Berkshire Hathaway Sells ~1.22M DVA Shares: Berkshire disclosed a sale of ~1.22M shares on May 1, 2026 (filed May 5), reducing its stake to ~28.9M shares. This was pursuant to DVA’s pre-existing repurchase agreement with Berkshire.
• Implication: Planned/contractual sale, not a discretionary signal; DVA repurchased ~5M total shares in and shortly after Q1, including this Berkshire block.

7. Peer Commentaries — Current-Quarter Read-Through (Last 60 Days)

Key Takeaway: The most direct read-through comes from

Key Takeaway: The most direct read-through comes from Fresenius Medical Care (FMS), which reported Q2 2026 results today (August 3) and confirmed its full-year 2026 outlook unchanged, with Care Delivery OI up 23% at constant currency — a strong positive signal for dialysis industry economics. Broader healthcare peers (DGX, LH, UHS) provide useful context on ACA/payer-mix trends and US healthcare utilization, but are less directly comparable to DVA’s dialysis-specific dynamics.

Note on scope: Only commentary about the current reporting quarter (Q2 2026) or forward-looking commentary made after Q1 2025 earnings is included below. Backward-looking Q1 2025 results commentary from peers is excluded.

Fresenius Medical Care (FMS) — Q2 2026 Earnings Release (August 3, 2026)

Relevance: HIGHEST — Direct dialysis peer, same calendar quarter.

• Full-year 2026 outlook confirmed unchanged: FMS stated it "confirms its unchanged financial outlook for the full year 2026," with the outlook assuming "current laws/policies/regulations and tariffs." This is a direct positive read-through for DVA: no deterioration in the reimbursement environment, no regulatory surprises, and no macro-driven guidance cut from the largest global dialysis operator.
• Care Delivery OI up 23% at constant currency in Q2 2026: FMS reported Q2 operating income (ex-special items) of EUR 569M, up 23% at constant currency, "driven by stronger operating income growth in the Care Delivery segment than expected by the capital market." Group revenue grew 4% at constant currency to EUR 4,861M.
• Read-through for DVA: The Care Delivery outperformance at FMS is a meaningful positive signal — it suggests that dialysis-specific economics (volume, reimbursement, cost management) were favorable in Q2 2026, consistent with DVA’s own guidance for the quarter. The magnitude of the FMS beat ("stronger than expected by the capital market") raises the probability that DVA also outperforms on its dialysis segment.
• Stable regulatory/reimbursement assumption: FMS’s explicit statement that its outlook assumes "current laws/policies/regulations and tariffs" implies no adverse CMS bundle changes or ACA-related disruptions were material enough to alter their guidance — a reassuring backdrop for DVA’s own ACA headwind narrative.

Quest Diagnostics (DGX) — Q2 2026 Earnings Call (July 23, 2026)

Relevance: MODERATE — Broader healthcare services; kidney testing partnership with FMS; ACA/payer-mix read-through.

• ACA exchange enrollment down >20%, but impact manageable: DGX noted ACA enrollment is "down north of 20%" but "not translating into our business" in a major way — the healthier patients dropped off while sicker patients remained, keeping revenue "flattish from a revenue standpoint." DGX is still assuming a "30 basis point impact on revenue from the ACA exchange subsidy expiration" for full-year 2026.
• Read-through for DVA: The DGX data point that sicker/higher-acuity patients are retaining coverage is a nuanced positive for DVA — ESRD patients are among the highest-acuity patients and are less likely to voluntarily drop coverage. However, DVA’s specific concern is patients shifting to lower-tier bronze plans (higher out-of-pocket costs, lower RPT), which DGX does not directly address.
• US healthcare utilization remains strong: DGX reported "mid-single digit growth" in its hospital reference business and "high single digit" growth in its core physician and consumer businesses. Volumes "three weeks into July" were "consistent with what we saw in the second quarter," with "no assumption of any slowdown or anything different on utilization" for H2 2026.
• Read-through for DVA: Strong overall healthcare utilization is a positive backdrop for dialysis treatment volumes, though DVA’s volume is more driven by patient census (mortality, admits) than general utilization trends.
• Fresenius kidney testing partnership growing: DGX noted its Fresenius Medical Care relationship "contributed 9% to volume in the quarter" and is expected to generate "close to $100 million" in revenue for the year, with margin profile "continuing to improve from Q1 to Q2 to Q3 and into Q4." DGX highlighted its "comprehensive kidney testing portfolio spanning risk assessment to post-transplant monitoring."
• Read-through for DVA: The growing DGX-FMS kidney testing partnership reflects increasing diagnostic intensity in the CKD/ESRD population — consistent with DVA’s own narrative around higher-acuity patients and the clinical innovation opportunity.

LabCorp (LH) — Q2 2026 Earnings Call (July 30, 2026)

Relevance: MODERATE — Broader healthcare services; ACA/payer-mix and utilization read-through.

• ACA headwind tracking as expected, bad debt stable: LH continues to factor in a "30 basis point" volume impact from ACA/Medicaid changes for full-year 2026, with Q2 showing "a slight headwind of about 20 to 30 basis points." Bad debt "remains consistent" and "in line with prior year," with no deterioration in collections.
• Read-through for DVA: The ACA headwind tracking in-line (not worse) at LH is a mild positive for DVA’s own $40M headwind assumption — consistent with management’s Q1 commentary that the headwind is "trending a little better" than the placeholder.
• Diagnostics volume growth strong, tests per patient rising: LH Diagnostics revenue grew 5.5% with volume up 3%, and "tests for accession continue to increase" driven by higher-acuity specialty patients. LH cited "the aging population, the health and wellness trend, the advancement in diagnostic testing" as structural tailwinds.
• Read-through for DVA: Rising diagnostic intensity in chronic disease patients (including CKD/ESRD) is consistent with DVA’s IKC value-based care thesis and the broader trend toward more comprehensive kidney care management.
• Kidney transplant diagnostics innovation: LH signed an agreement to broaden access to "my Alaris KTDX, a first-of-its-kind, non-invasive test that supports surveillance of graft injury, including rejection following a kidney transplant." This reflects ongoing innovation in kidney care diagnostics.
• Read-through for DVA: Directionally positive for the kidney care ecosystem; not a direct Q2 earnings driver for DVA.

Universal Health Services (UHS) — Q2 2026 Earnings Call (July 28, 2026)

Relevance: LIMITED — Acute care hospital operator; ACA/payer-mix and labor cost read-through only.

• ACA exchange volumes down ~15%, impact worse than initially expected: UHS reported that exchange volumes declined approximately 15% in Q2 2026, with an estimated $20M impact in the quarter. Critically, UHS observed that "virtually everyone who lost their exchange coverage became an uninsured patient" — the assumed 10–20% conversion to employer coverage did not materialize. Full-year ACA impact now expected at ~$85M (vs. original $75M guidance).
• Read-through for DVA: This is the most cautionary data point in the peer set for DVA. If the pattern of lost exchange patients becoming uninsured (rather than finding alternative coverage) holds in the dialysis population, DVA’s $40M commercial mix headwind could prove conservative. However, ESRD patients have a stronger incentive to maintain coverage given the cost of dialysis, and Medicare/Medicaid serves as a backstop — so the UHS dynamic may not translate directly.
• Acute care volumes rebounded in Q2, but full-year guidance trimmed: UHS reported adjusted admissions up 2.9% YoY in Q2, with volume performance "improved sequentially from Q1." However, full-year volume guidance was trimmed to 1.5–2.5% (from 2–3%), reflecting "continued shift of certain elective and outpatient procedures into alternate site settings."
• Read-through for DVA: The acute care volume rebound is a mild positive for DVA’s admits pipeline (hospital discharges are a key source of new dialysis patients), but the guidance trim suggests the recovery is not as strong as initially hoped.
• Labor costs moderating: UHS reported SWB per adjusted admission up 2.7% YoY, with contract labor at 2.5% of revenue (down 20 bps YoY). Headcount and labor cost growth "expected to continue to moderate during the second half."
• Read-through for DVA: Consistent with DVA’s own labor productivity narrative — the broader healthcare labor market appears to be normalizing, supporting DVA’s cost management outlook.

8. Insider Transaction Activity

Key Takeaway: The insider picture is dominated by

Key Takeaway: The insider picture is dominated by post-earnings open-market sales by the CEO and CFO at prices well below current levels (~$193–$211 vs. ~$240 today), which is notable but not alarming given the post-blackout timing. The Berkshire sale was contractual (pre-existing repurchase agreement). No open-market buys have been filed since Q1 earnings.

Analysis: The cluster of discretionary open-market sales by the CEO (69,407 shares combined), CFO (51,471 shares), and COO (20,529 shares) in the days and weeks immediately following Q1 earnings is worth flagging. All three sold at prices in the $193–$211 range — well below the current ~$240 level — suggesting they did not anticipate the subsequent 15–20% additional appreciation. This is not unusual behavior for executives selling in the post-blackout window after a large earnings beat, but the concentration of discretionary sales (vs. 10b5-1 planned sales) across three senior executives in a short window is notable. The Berkshire sale is contractual and should not be read as a negative signal. No open-market buys have been filed by any insider since Q1 earnings. Source: Insider Transaction Data (SEC Form 4 Filings).